|
|
|
Insider
Information: |
Orbimed Genesis Gp Llc |
Relationship: |
Director, 10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
14 |
|
Direct
Shares |
0 |
|
Indirect Shares
|
58,578,510 |
|
|
Direct
Value |
$0 |
|
|
Indirect Value
|
$284,227,743 |
|
|
Total
Shares |
58,578,510 |
|
|
Total
Value |
$284,227,743 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
|
|
Stock
price went down : |
|
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Keros Therapeutics, Inc. |
KROS |
Director |
2020-04-13 |
0 |
2020-04-13 |
1,119,812 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2020-05-21 |
0 |
2022-11-25 |
5,559,528 |
Premium* |
|
Logicbio Therapeutics, Inc. |
LOGC |
Director, 10% Owner |
2020-10-01 |
0 |
2020-10-01 |
296,296 |
Premium* |
|
Galecto Inc. |
GLTO |
Director, 10% Owner |
2020-11-02 |
0 |
2020-11-02 |
1,031,811 |
Premium* |
|
Edgewise Therapeutics, Inc. |
EWTX |
Director, 10% Owner |
|
0 |
2024-01-23 |
14,756,096 |
Premium* |
|
Ikena Oncology, Inc. |
IKNA |
Director |
2021-03-30 |
0 |
2023-08-04 |
7,928,543 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2021-09-17 |
0 |
2024-01-11 |
2,680,496 |
Premium* |
|
Theseus Pharmaceuticals, Inc. |
THRX |
Director, 10% Owner |
2021-10-12 |
0 |
2024-02-14 |
0 |
Premium* |
|
Janux Therapeutics, Inc. |
JANX |
Director |
2021-12-16 |
0 |
2021-12-29 |
231,098 |
Premium* |
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2022-01-26 |
0 |
2022-01-26 |
226,704 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2022-05-26 |
0 |
2023-11-22 |
6,475,291 |
Premium* |
|
Terns Pharmaceuticals, Inc. |
TERN |
Director, 10% Owner |
2022-08-16 |
0 |
2022-12-23 |
7,619,135 |
Premium* |
|
Disc Medicine, Inc |
IRON |
Director |
2023-12-18 |
0 |
2023-12-18 |
1,702,237 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Director, 10% Owner |
2023-02-23 |
0 |
2023-05-17 |
8,951,463 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
56 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
KROS |
Keros Therapeutics, Inc. |
Director |
|
2020-04-13 |
4 |
A |
$0.00 |
$0 |
I/I |
893,534 |
148,922 |
0 |
- |
|
KROS |
Keros Therapeutics, Inc. |
Director |
|
2020-04-13 |
4 |
B |
$16.00 |
$6,003,200 |
I/I |
375,200 |
1,119,812 |
2.1 |
- |
|
SCPH |
Scpharmaceuticals Inc. |
10% Owner |
|
2020-05-21 |
4 |
B |
$8.65 |
$11,999,998 |
I/I |
1,387,283 |
231,200 |
1.5 |
- |
|
LOGC |
Logicbio Therapeutics, In... |
Director |
|
2020-10-01 |
4 |
B |
$6.00 |
$8,888,892 |
I/I |
1,481,482 |
296,296 |
2.25 |
- |
|
GLTO |
Galecto Inc. |
Director |
|
2020-11-02 |
4 |
B |
$15.00 |
$10,999,995 |
I/I |
733,333 |
1,031,811 |
2.25 |
- |
|
GLTO |
Galecto Inc. |
Director |
|
2020-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,069,922 |
191,787 |
0 |
- |
|
EWTX |
Edgewise Therapeutics, In... |
Director |
|
2021-03-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
316,920 |
|
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2021-03-30 |
4/A |
A |
$0.00 |
$0 |
I/I |
5,586,311 |
157,288 |
0 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2021-03-30 |
4/A |
B |
$16.00 |
$6,774,400 |
I/I |
423,400 |
91,014 |
2.1 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2021-03-30 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,513,486 |
42,614 |
0 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
5,214,394 |
130,924 |
0 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2021-03-30 |
4 |
B |
$16.00 |
$6,774,400 |
I/I |
423,400 |
117,378 |
2.1 |
- |
|
IKNA |
Ikena Oncology, Inc. |
Director |
|
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,885,403 |
68,978 |
0 |
- |
|
EWTX |
Edgewise Therapeutics, In... |
Director |
|
2021-03-30 |
4 |
B |
$16.00 |
$5,750,000 |
I/I |
359,375 |
13,359,456 |
2.25 |
- |
|
EWTX |
Edgewise Therapeutics, In... |
Director |
|
2021-03-30 |
4 |
A |
$0.00 |
$0 |
I/I |
13,002,760 |
272,724 |
0 |
- |
|
ALPN |
Alpine Immune Sciences In... |
Director |
|
2021-09-17 |
4 |
B |
$9.40 |
$9,499,988 |
I/I |
1,010,637 |
425,531 |
2.25 |
% |
|
THRX |
Theseus Pharmaceuticals, ... |
10% Owner |
|
2021-10-12 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
499,150 |
1.5 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
10% Owner |
|
2021-10-12 |
4 |
A |
$0.00 |
$0 |
I/I |
16,213,668 |
436,650 |
0 |
- |
|
JANX |
Janux Therapeutics, Inc. |
Director |
|
2021-12-16 |
4 |
S |
$19.07 |
$7,500,231 |
I/I |
(393,300) |
245,898 |
0 |
- |
|
JANX |
Janux Therapeutics, Inc. |
Director |
|
2021-12-21 |
4 |
S |
$19.00 |
$2,268,600 |
I/I |
(119,400) |
234,798 |
0 |
- |
|
JANX |
Janux Therapeutics, Inc. |
Director |
|
2021-12-29 |
4 |
S |
$20.30 |
$820,120 |
I/I |
(40,400) |
231,098 |
0 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-11 |
4 |
B |
$9.81 |
$89,319 |
I/I |
8,500 |
16,348,018 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-12 |
4 |
B |
$10.06 |
$190,104 |
I/I |
18,897 |
16,366,915 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-13 |
4 |
B |
$9.43 |
$163,328 |
I/I |
17,320 |
16,384,235 |
2.25 |
- |
|
THRX |
Theseus Pharmaceuticals, ... |
Director |
|
2022-01-19 |
4 |
B |
$9.97 |
$114,864 |
I/I |
11,521 |
16,395,756 |
2.25 |
- |
|
56 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|